stoxline Quote Chart Rank Option Currency Glossary
Century Therapeutics, Inc. (IPSC)
3.26  0.01 (0.31%)    06-12 16:00
Open: 3.35
High: 3.44
Volume: 421,959
Pre. Close: 3.25
Low: 3.22
Market Cap: 271(M)
Technical analysis
2024-06-12 4:23:00 PM
Short term     
Mid term     
Targets 6-month :  4.05 1-year :  4.73
Resists First :  3.47 Second :  4.05
Pivot price 3.12
Supports First :  3.08 Second :  2.84
MAs MA(5) :  3.16 MA(20) :  3.1
MA(100) :  3.78 MA(250) :  2.98
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  70.4 D(3) :  54.8
RSI RSI(14): 53.2
52-week High :  5.51 Low :  1.27
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ IPSC ] has closed below upper band by 25.8%. Bollinger Bands are 52.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.44 - 3.46 3.46 - 3.47
Low: 3.18 - 3.2 3.2 - 3.22
Close: 3.23 - 3.26 3.26 - 3.29
Company Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Headline News

Tue, 11 Jun 2024
Avidity Partners Management LP Increases Stock Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - MarketBeat

Thu, 06 Jun 2024
Gregory Russotti Sells 5,000 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) Stock - MarketBeat

Wed, 05 Jun 2024
Century Therapeutics (NASDAQ:IPSC) Given Buy Rating at HC Wainwright - Defense World

Tue, 04 Jun 2024
5 Analysts Assess Century Therapeutics: What You Need To Know - Century Therapeutics (NASDAQ:IPSC) - Benzinga

Mon, 03 Jun 2024
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting - GlobeNewswire

Fri, 10 May 2024
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at ... - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 83 (M)
Held by Insiders 3.705e+007 (%)
Held by Institutions 28.6 (%)
Shares Short 1,730 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.1105e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -3 %
Return on Assets (ttm) 661.8 %
Return on Equity (ttm) -19.4 %
Qtrly Rev. Growth 1.37e+006 %
Gross Profit (p.s.) -34.69
Sales Per Share -40.46
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -89 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0.1
Price to Book value 0
Price to Sales -0.09
Price to Cash Flow 1.72
Stock Dividends
Dividend 0
Forward Dividend 1.56e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android